146 related articles for article (PubMed ID: 31331091)
1. Autoantibodies Specific to ERα are Involved in Tamoxifen Resistance in Hormone Receptor Positive Breast Cancer.
Maselli A; Parlato S; Puglisi R; Raggi C; Spada M; Macchia D; Pontecorvi G; Iessi E; Pagano MT; Cirulli F; Gabriele L; Carè A; Vici P; Pizzuti L; Barba M; Matarrese P; Pierdominici M; Ortona E
Cells; 2019 Jul; 8(7):. PubMed ID: 31331091
[TBL] [Abstract][Full Text] [Related]
2. Measuring IGF-1, ER-α and EGFR expression can predict tamoxifen-resistance in ER-positive breast cancer.
Chong K; Subramanian A; Sharma A; Mokbel K
Anticancer Res; 2011 Jan; 31(1):23-32. PubMed ID: 21273576
[TBL] [Abstract][Full Text] [Related]
3. Loss of Estrogen-Regulated
Zhang W; Wu M; Chong QY; Zhang M; Zhang X; Hu L; Zhong Y; Qian P; Kong X; Tan S; Li G; Ding K; Lobie PE; Zhu T
Cancer Res; 2018 Sep; 78(17):4915-4928. PubMed ID: 29945962
[TBL] [Abstract][Full Text] [Related]
4. Activity of the antiestrogenic cajanin stilbene acid towards breast cancer.
Fu Y; Kadioglu O; Wiench B; Wei Z; Wang W; Luo M; Yang X; Gu C; Zu Y; Efferth T
J Nutr Biochem; 2015 Nov; 26(11):1273-82. PubMed ID: 26365581
[TBL] [Abstract][Full Text] [Related]
5. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
[No Abstract] [Full Text] [Related]
6. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
7. Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines.
Kim J; Lee J; Jang SY; Kim C; Choi Y; Kim A
Oncol Rep; 2016 May; 35(5):2553-60. PubMed ID: 26986571
[TBL] [Abstract][Full Text] [Related]
8. Association of ERα-36 expression with the de novo resistance of tamoxifen in ER-positive breast cancer.
Juliansyah A; Rahman S; Indra I; Nelwan B; Prihantono P
Breast Dis; 2021; 40(S1):S123-S127. PubMed ID: 34057127
[TBL] [Abstract][Full Text] [Related]
9. Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.
Bostner J; Alayev A; Berman AY; Fornander T; Nordenskjöld B; Holz MK; Stål O
Breast Cancer Res Treat; 2018 Feb; 168(1):17-27. PubMed ID: 29128895
[TBL] [Abstract][Full Text] [Related]
10. Endocrine therapy resistance can be associated with high estrogen receptor alpha (ERalpha) expression and reduced ERalpha phosphorylation in breast cancer models.
Kuske B; Naughton C; Moore K; Macleod KG; Miller WR; Clarke R; Langdon SP; Cameron DA
Endocr Relat Cancer; 2006 Dec; 13(4):1121-33. PubMed ID: 17158758
[TBL] [Abstract][Full Text] [Related]
11. Oestrogen receptor-regulated glutathione S-transferase mu 3 expression attenuates hydrogen peroxide-induced cytotoxicity, which confers tamoxifen resistance on breast cancer cells.
Lin JH; Tu SH; Chen LC; Huang CC; Chang HL; Cheng TC; Chang HW; Wu CH; Wu HC; Ho YS
Breast Cancer Res Treat; 2018 Nov; 172(1):45-59. PubMed ID: 30054830
[TBL] [Abstract][Full Text] [Related]
12. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
[TBL] [Abstract][Full Text] [Related]
13. MiR-873 regulates ERα transcriptional activity and tamoxifen resistance via targeting CDK3 in breast cancer cells.
Cui J; Yang Y; Li H; Leng Y; Qian K; Huang Q; Zhang C; Lu Z; Chen J; Sun T; Wu R; Sun Y; Song H; Wei X; Jing P; Yang X; Zhang C
Oncogene; 2015 Jul; 34(30):3895-907. PubMed ID: 25531331
[TBL] [Abstract][Full Text] [Related]
14. Menin, a product of the MENI gene, binds to estrogen receptor to enhance its activity in breast cancer cells: possibility of a novel predictive factor for tamoxifen resistance.
Imachi H; Murao K; Dobashi H; Bhuyan MM; Cao X; Kontani K; Niki S; Murazawa C; Nakajima H; Kohno N; Yamashita H; Iwase H; Hayashi S; Ishida T; Yamauchi A
Breast Cancer Res Treat; 2010 Jul; 122(2):395-407. PubMed ID: 19847644
[TBL] [Abstract][Full Text] [Related]
15. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
16. Norcantharidin regulates ERα signaling and tamoxifen resistance via targeting miR-873/CDK3 in breast cancer cells.
Zhang X; Zhang B; Zhang P; Lian L; Li L; Qiu Z; Qian K; Chen A; Liu Q; Jiang Y; Cui J; Qi B
PLoS One; 2019; 14(5):e0217181. PubMed ID: 31120927
[TBL] [Abstract][Full Text] [Related]
17. Relationship between intratumoral expression of genes coding for xenobiotic-metabolizing enzymes and benefit from adjuvant tamoxifen in estrogen receptor alpha-positive postmenopausal breast carcinoma.
Bièche I; Girault I; Urbain E; Tozlu S; Lidereau R
Breast Cancer Res; 2004; 6(3):R252-63. PubMed ID: 15084249
[TBL] [Abstract][Full Text] [Related]
18. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
19. Selective Human Estrogen Receptor Partial Agonists (ShERPAs) for Tamoxifen-Resistant Breast Cancer.
Xiong R; Patel HK; Gutgesell LM; Zhao J; Delgado-Rivera L; Pham TND; Zhao H; Carlson K; Martin T; Katzenellenbogen JA; Moore TW; Tonetti DA; Thatcher GRJ
J Med Chem; 2016 Jan; 59(1):219-237. PubMed ID: 26681208
[TBL] [Abstract][Full Text] [Related]
20. Oxidative stress contributes to the tamoxifen-induced killing of breast cancer cells: implications for tamoxifen therapy and resistance.
Bekele RT; Venkatraman G; Liu RZ; Tang X; Mi S; Benesch MG; Mackey JR; Godbout R; Curtis JM; McMullen TP; Brindley DN
Sci Rep; 2016 Feb; 6():21164. PubMed ID: 26883574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
